Combination of mifepristone and misoprostol for termination of 8-16 weeks' pregancy: a multicenter, randomized controlled study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-11001438

Enrollment

Unknown

Registered

2011-07-08

Start date

2010-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

medical abortion for 8-16 weeks' pregnancy

Interventions

A:Day 1: mifepristone 200mg

Day 2: misoprostol vaginally 600mcg, q3h, up to 4 times

B:Day 1: mifeprisone 200mg

Day 2: misoprostol vaginal 600mcg, then misoprostol orally after 3 h , up to 4 times

C:Day 1: mifepristone 200mg

Day 2: misoprostol orally 600mcg, q3h, up to 4 times

D:Day 1: mifepristone 100mg

Day 2: mifepristone 100mg

Day3: misoprostol 600mcg vaginal, q12h, up tp 3 times

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: healthy women at 8-16 weeks pregant

Exclusion criteria

Exclusion criteria: abnormal vaginal bleeding, with serious medical diseases, genital tract infection, genital tract tumor, allergy to mifepristone or misoprostol

Design outcomes

Primary

Measure	Time frame
successful rate of medical abortion;	—

Secondary

Measure	Time frame
induction-to-abortion interval;adverse event;	—

Countries

China

Contacts

Public ContactLinan CHENG

linanc2@163.com+86 021-64438459

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026